Paris-based Inato, which offers a marketplace to connect pharmaceutical companies with clinical trial sites, raised a $20M Series A2 led by Cathay Innovation
Emily Olsen / MobiHealthNews :
Context & Ripple Effects
Inato's raise slots into a two-year run of big checks for clinical-trial infrastructure: Reify Health pulled in a $220M Series D at a $4.8B+ valuation last spring, and earlier rounds went to site-side and analytics plays like Hawthorne Effect's $20M Series A and Aetion's $110M Series C for real-world evidence.
The France angle matters too — Owkin's $180M raise backed by Sanofi showed French life-sciences tech attracting strategic pharma money, and Inato now adds a Paris-based marketplace play to that cluster, attacking the trial bottleneck from the site side rather than the patient side.
First-order effects
- Inato gains $20M led by Cathay Innovation to scale its marketplace connecting pharmaceutical companies with clinical trial sites — capital aimed squarely at expanding the supply side of trial capacity.
Second-order effects
- Pharma sponsors now choose between competing intermediaries across the trial funnel: patient-matching platforms like Trialjectory, device-data analytics like Koneksa, and Inato's site marketplace — pushing each to bundle more of the recruitment workflow or compete on price.
Third-order effects
- If the funding pattern holds, clinical trial recruitment consolidates around platform intermediaries on both sides of the match — patients and sites — shifting leverage over where and how trials run from individual research sites toward whoever owns the marketplace.
The trend: Clinical-trial software keeps absorbing venture capital through the downturn, with successive rounds targeting each bottleneck in sequence — data, patients, devices, and now trial-site supply.